Background and Decision on Relaxing Peptide Formulation Regulations

The U.S. Food and Drug Administration (FDA) is pushing forward with plans to reclassify or remove from regulation 12 to 14 substances, including BPC-157, Thymosin Alpha-1, and TB-500, among the 19 peptides previously categorized as Category 2 due to safety concerns and a lack of scientific evidence. This decision follows the policy declaration by the Department of Health and Human Services (HHS) in February 2026 and aims to absorb the demand from the illicit 'Research Peptide' market, which has been operating online, into the regulated framework of compounding pharmacies. This reflects a strong commitment to bringing patients who have been exposed to the risks of the unregulated black market under the control of regulatory authorities, thereby strengthening the public health safety net.

Impact on the Market and Key Companies

The relaxation of regulations is expected to primarily benefit companies that operate 503A compounding pharmacies and 503B outsourcing facilities, as defined by the U.S. Federal Food, Drug, and Cosmetic Act (FD&C Act). Companies like Fagron (Fagron, FAGR.BR), a leading global supplier of compounding ingredients, and Hims & Hers Health (HIMS), which provides telehealth and compounding pharmacy services, are poised to experience immediate market expansion. With the rapid increase in consumer demand for peptide-based anti-aging and wellness treatments, these companies, which have secured a legitimate supply chain, are likely to see accelerated revenue growth. In contrast, smaller companies that have been dealing with the five remaining regulated substances, such as Melanotan II and GHRP-2, will inevitably suffer significant losses.

Significance of the Upcoming PCAC Official Review

Following this action, the FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23 and 24, 2026, to officially review whether these peptides should be included in the 503A compounding allowance list (Bulks List). The scientific review by the advisory committee will determine the permanent legal compounding rights for each peptide ingredient, and the industry and investors are paying close attention to this meeting. If the committee provides a positive assessment and the peptides are ultimately included on the list, compounding pharmacies will obtain a strong regulatory exemption, allowing them to legally manufacture and distribute customized medications without going through the clinical trial phase. This is expected to be a decisive turning point in resolving the regulatory uncertainty in the peptide industry.

Patient Safety and Long-Term Market Outlook

Patients will now be able to obtain rigorously tested peptide medications through prescriptions from licensed pharmacies, rather than through unregulated and potentially unsafe channels. This is expected to significantly reduce the risk of health hazards, such as microbial contamination and medication errors, that have been associated with the black market. In the long term, this will lead to greater transparency and trust in the U.S. compounding drug market, and the market will be reshaped by large raw material suppliers that can demonstrate the safety and quality of their products. A structural change is expected, with major players with strong quality assurance capabilities further strengthening their market dominance.